IVVD
HEALTHCAREInvivyd Inc
$1.46+0.07 (+5.04%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IVVD Today?
No stock-specific AI insight has been generated for IVVD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.48$3.07
$1.46
Fundamentals
Market Cap$413M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume2.7M
Avg Volume (10D)—
Shares Outstanding282.8M
IVVD News
20 articles- Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026Yahoo Finance·May 7, 2026
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 5, 2026
- Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 TreatmentYahoo Finance·Apr 24, 2026
- Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care SummitYahoo Finance·Apr 20, 2026
- Stock Market Today, April 9: Markets Extend Gains as Ceasefire HoldsMotley Fool·Apr 9, 2026
- Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063Marketbeat·Apr 9, 2026
- Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of MeaslesYahoo Finance·Apr 9, 2026
- Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune HealthYahoo Finance·Apr 7, 2026
- Invivyd Announces Presentation at the World Vaccine Congress WashingtonYahoo Finance·Mar 30, 2026
- Exploring Three High Growth Tech Stocks In The US MarketYahoo Finance·Mar 27, 2026
- Invivyd Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Invivyd Inc (IVVD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...Yahoo Finance·Mar 5, 2026
- Invivyd, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
- Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial UpdatesYahoo Finance·Mar 5, 2026
- Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical OfficerYahoo Finance·Mar 5, 2026
- Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026Yahoo Finance·Mar 2, 2026
- MannKind (MNKD) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 26, 2026
- New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 AntibodiesYahoo Finance·Feb 24, 2026
- Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 17, 2026
- Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-AdministrationYahoo Finance·Feb 3, 2026
All 20 articles loaded
Price Data
Open$1.48
Previous Close$1.39
Day High$1.55
Day Low$1.44
52 Week High$3.07
52 Week Low$0.48
52-Week Range
$0.48$3.07
$1.46
Fundamentals
Market Cap$413M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume2.7M
Avg Volume (10D)—
Shares Outstanding282.8M
About Invivyd Inc
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—